Bim Antibody

ProSci
Product Code: PSI-2065
Product Group: Primary Antibodies
Supplier: ProSci

CodeSizePrice
PSI-2065-0.02mg0.02mg£150.00
Quantity:
PSI-2065-0.1mg0.1mg£449.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Immunohistochemistry (IHC)
  • Western Blot (WB)

Images

1 / 13
<strong>Figure 1 Western Blot Validation in Human Cell Lines</strong><br>
Loading: 15 μg of lysates per lane.
Antibodies: BIM 2065, (0.5 μg/mL), 1h incubation at RT in 5% NFDM/TBST.
Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
2 / 13
<strong>Figure 2 Independent Antibody Validation (IAV) via Protein Expression Profile in Cell Lines</strong><br>
Loading: 15 μg of lysates per lane.
Antibodies: BIM 2065, (0.5 μg/mL), BIM 3405, (5 μg/mL), beta-actin (1 μg/mL) and GAPDH (0.02 μg/mL), 1h incubation at RT in 5% NFDM/TBST.
Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
3 / 13
<strong>Figure 3 Western Blot Validation in Human Tissue</strong><br>
Loading: 15 μg of lysates per lane.
Antibodies: BIM 2065, (0.5 μg/mL), 1h incubation at RT in 5% NFDM/TBST.
Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
Lane 1: Human thymus
Lane 2: Human colon
4 / 13
<strong>Figure 4 Western Blot Validation in HeLa Cells</strong><br>
Loading: 15 μg of lysate per lane.
Antibodies: BIM 2065, (0.5 μg/mL), 1h incubation at RT in 5% NFDM/TBST.
Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
BIM 2065 can detect all three human isoforms, including EL, L and S isoforms.
5 / 13
<strong>Figure 5 Western Blot Validation in Rat Myeloma Cell line</strong><br>
Loading: 15 μg of rat myeloma YB2/0 cell lysate per lane.
Antibodies: BIM 2065, (0.5 μg/mL), 1h incubation at RT in 5% NFDM/TBST.
Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
6 / 13
<strong>Figure 6 Immunofluorescence Validation of BIM in K562 Cells</strong><br>
Immunofluorescent analysis of 4% paraformaldehyde-fixed K562 cells labeling Bim with 2065 at 20 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red).
7 / 13
<strong>Figure 7 Immunohistochemistry Validation of BIM in Human Skin Cancer Cells</strong><br> 
Immunohistochemical analysis of paraffin-embedded human spleen tissue using anti-BIM antibody (2065) at 20 μg/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.
8 / 13
<strong>Figure 8 Induced Expression Validation of BIM in Mouse Hippocampus (Tsuchiya et al., 2011) </strong><br>
The induction of Bim protein was detected by immunohistochemical analysis of mice after i.h. injection of epoxomicin with anti-BIM antibodies. Sections from epoxomicin-treated animals exhibited cells staining positive for Bim expression within the NeuN-positive population of neurons in the CA1 of the ipsilateral side. In contrast, Bim-positive cells were absent within the NeuNpositive
CA1 neurons on the contralateral side.
9 / 13
<strong>Figure 9 KD Validation of BIM in 293 Cells (Han et al., 2010) </strong><br>
Immunofluorescence analysis with anti-BIM antibodies was performed for BIM in 293 cells transfected with control siRNA or BIM siRNA. BIM expression was disrupted after BIM siRNA knockdown.
10 / 13
<strong>Figure 10 Regulated Expression Validation of BIM in U266 Cells (Chen et al., 2012) </strong><br>
Immunoblot analysis was carried out to monitor protein expression of 3 isoforms (EL, L, and S) of Bim with anti-BIM antibodies. BIM expression was up-regulated by flavopiridol treatment, which was blocked by Cycloheximide in U266 cells.
11 / 13
<strong>Figure 11 WB KD Validation of BIM in 293 Cells (Han et al., 2010) </strong><br>
Western blot analysis with anti-BIM antibodies was performed for BIM in 293 cells transfected with control siRNA or BIM siRNA. BIM expression was disrupted after BIM siRNA knockdown.
12 / 13
<strong>Figure 12 KD Validation of BIM in Human Cell Lines (Chen et al., 2009) </strong><br>
Human leukemia (U937 and Jurkat) and myeloma (U266) cells were stably transfected with constructs encoding shBim or a scrambled sequence (shNC). Immunoblotting was preformed to monitor expression of Bim in these cells with anti-BIM antibodies. BIM expression was disrupted after shBIM knockdown.
13 / 13
<strong>Figure 13 Localization Validation of BIM in Mouse Macrophages (Ulett et al., 2005) </strong><br>
Immunoblots of subcellular fractions enriched for mitochondria and cytosol were used to determine BIM protein levels with anti-BIM antibodies in J774A cells. BIM is exclusively expressed in mitochondria

<strong>Figure 1 Western Blot Validation in Human Cell Lines</strong><br>
Loading: 15 μg of lysates per lane.
Antibodies: BIM 2065, (0.5 μg/mL), 1h incubation at RT in 5% NFDM/TBST.
Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
<strong>Figure 2 Independent Antibody Validation (IAV) via Protein Expression Profile in Cell Lines</strong><br>
Loading: 15 μg of lysates per lane.
Antibodies: BIM 2065, (0.5 μg/mL), BIM 3405, (5 μg/mL), beta-actin (1 μg/mL) and GAPDH (0.02 μg/mL), 1h incubation at RT in 5% NFDM/TBST.
Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
<strong>Figure 3 Western Blot Validation in Human Tissue</strong><br>
Loading: 15 μg of lysates per lane.
Antibodies: BIM 2065, (0.5 μg/mL), 1h incubation at RT in 5% NFDM/TBST.
Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
Lane 1: Human thymus
Lane 2: Human colon
<strong>Figure 4 Western Blot Validation in HeLa Cells</strong><br>
Loading: 15 μg of lysate per lane.
Antibodies: BIM 2065, (0.5 μg/mL), 1h incubation at RT in 5% NFDM/TBST.
Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
BIM 2065 can detect all three human isoforms, including EL, L and S isoforms.
<strong>Figure 5 Western Blot Validation in Rat Myeloma Cell line</strong><br>
Loading: 15 μg of rat myeloma YB2/0 cell lysate per lane.
Antibodies: BIM 2065, (0.5 μg/mL), 1h incubation at RT in 5% NFDM/TBST.
Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
<strong>Figure 6 Immunofluorescence Validation of BIM in K562 Cells</strong><br>
Immunofluorescent analysis of 4% paraformaldehyde-fixed K562 cells labeling Bim with 2065 at 20 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red).
<strong>Figure 7 Immunohistochemistry Validation of BIM in Human Skin Cancer Cells</strong><br> 
Immunohistochemical analysis of paraffin-embedded human spleen tissue using anti-BIM antibody (2065) at 20 μg/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.
<strong>Figure 8 Induced Expression Validation of BIM in Mouse Hippocampus (Tsuchiya et al., 2011) </strong><br>
The induction of Bim protein was detected by immunohistochemical analysis of mice after i.h. injection of epoxomicin with anti-BIM antibodies. Sections from epoxomicin-treated animals exhibited cells staining positive for Bim expression within the NeuN-positive population of neurons in the CA1 of the ipsilateral side. In contrast, Bim-positive cells were absent within the NeuNpositive
CA1 neurons on the contralateral side.
<strong>Figure 9 KD Validation of BIM in 293 Cells (Han et al., 2010) </strong><br>
Immunofluorescence analysis with anti-BIM antibodies was performed for BIM in 293 cells transfected with control siRNA or BIM siRNA. BIM expression was disrupted after BIM siRNA knockdown.
<strong>Figure 10 Regulated Expression Validation of BIM in U266 Cells (Chen et al., 2012) </strong><br>
Immunoblot analysis was carried out to monitor protein expression of 3 isoforms (EL, L, and S) of Bim with anti-BIM antibodies. BIM expression was up-regulated by flavopiridol treatment, which was blocked by Cycloheximide in U266 cells.
<strong>Figure 11 WB KD Validation of BIM in 293 Cells (Han et al., 2010) </strong><br>
Western blot analysis with anti-BIM antibodies was performed for BIM in 293 cells transfected with control siRNA or BIM siRNA. BIM expression was disrupted after BIM siRNA knockdown.
<strong>Figure 12 KD Validation of BIM in Human Cell Lines (Chen et al., 2009) </strong><br>
Human leukemia (U937 and Jurkat) and myeloma (U266) cells were stably transfected with constructs encoding shBim or a scrambled sequence (shNC). Immunoblotting was preformed to monitor expression of Bim in these cells with anti-BIM antibodies. BIM expression was disrupted after shBIM knockdown.
<strong>Figure 13 Localization Validation of BIM in Mouse Macrophages (Ulett et al., 2005) </strong><br>
Immunoblots of subcellular fractions enriched for mitochondria and cytosol were used to determine BIM protein levels with anti-BIM antibodies in J774A cells. BIM is exclusively expressed in mitochondria

Further Information

Additional Names:
Bim Antibody: BAM, BIM, BOD, Bcl-2-like protein 11, Bcl2-interacting mediator of cell death, Bcl2-L-11
Application Note:
WB: 0.5 μg/mL; IHC-P: 20 μg/mL; IF: 20 μg/mL.

Antibody validated: Western Blot in human, mouse and rat samples; Immunohistochemistry in human samples; Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
Bim Antibody: Members in the Bcl-2 family are critical regulators of apoptosis by either inhibiting or promoting cell death. Bcl-2 homology 3 (BH3) domain is a potent death domain. BH3 domain containing pro-apoptotic proteins, including Bad, Bax, Bid, Bik, and Hrk, form a growing subclass of the Bcl-2 family. A novel BH3 domain containing protein was recently identified and designated Bim or BOD in human, mouse and rat. Bim/BOD interacts with diverse members in the pro-survival Bcl-2 sub-family including Bcl-2, Bcl-xL and Bcl-w. Bim/BOD induces apoptosis. The messenger RNA of Bim is ubiquitously expressed in multiple tissues and cell lines.
Background References:
  • O'Connor et al. EMBO J. 1998; 17:384-395.
  • Hsu et al. Mol. Endocrinol. 1998; 12:1432-40.
Buffer:
Bim Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/ml
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
Anti-BIM antibody (2065) was raised against a peptide corresponding to 20 amino acids near the amino terminus of human BIM.

The immunogen is located within the first 50 amino acids of BIM.
ISOFORMS:
Human BIM has 3 isoforms, including isoform EL (198aa, 22kD), isoform L (138aa, 16kD) and isoform S (108aa, 13kD). Mouse BIM has 3 isoforms, including isoform EL (196aa, 22kD), isoform L (140aa, 16kD) and isoform S (110aa, 13kD). Rat BIM has 4 isoforms, including isoform BOD-L (196aa, 22kD), isoform L (140aa, 16kD) and isoform BOD-M (110aa, 13kD). 2065 can detect all three isoforms.
NCBI Gene ID #:
10018
NCBI Official Name:
BCL2-like 11 (apoptosis facilitator)
NCBI Official Symbol:
BCL2L11
NCBI Organism:
Homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 22kD

Observed: 22kD
Protein Accession #:
O43521
Protein GI Number:
18202042
Purification:
Bim Antibody is affinity chromatography purified via peptide column.
Research Area:
Apoptosis
Swissprot #:
O43521
User NOte:
Optimal dilutions for each application to be determined by the researcher.
VALIDATION:

Independent Antibody Validation in Cell lines (Figure 2) shows similar BIM expression profile in human and mouse cell lines detected by two independent anti-BIM antibodies that recognize different epitopes, 2065 against N-terminus domain and 3405 against central domain.  BIM proteins are detected in the most tested cell lines at different expression levels by the two independent antibodies. 

KD validation (Figure 9, 11, 12): Anti-BIM antibody (2065) specificity was further verified by BIM specific knockdown. BIM signal in 293, U937, Jurkat and U266 cells transfected with BIM siRNAs or shRNA was disrupted in comparison with that in cells transfected with control siRNAs or shRNA.

Regulated expression validation (Figure 10): BIM expression detected by anit-BIM antibodies (2065) was up-regulated by flavopiridol treatment, which was blocked by Cycloheximide in U266 cells.

References

  1. Chen et al. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies. Cancer Res. 2012;72(16):4225-37. PMID: 22693249
  2. Tsuchiya et al. Bcl-2 homology domain 3-only proteins Puma and Bim mediate the vulnerability of CA1 hippocampal neurons to proteasome inhibition in vivo. Eur J Neurosci. 2011;33(3):401-8.PMID: 21198986
  3. Han et al. Regulation of mitochondrial apoptotic events by p53-mediated disruption of complexes between antiapoptotic Bcl-2 members and Bim. J Biol Chem. 2010;285(29):22473-83.PMID: 20404322
  4. Chen et al. Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1. Mol Cell Biol. 2009;29(23):6149-69. PMID: 19805519
  5. Ulett et al. Mechanisms of group B streptococcal-induced apoptosis of murine macrophages. J Immunol. 2005;175(4):2555-62.PMID: 16081829
  6. Dai et al. Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo. Blood. 2011;117(6):1947-57. PMID: 21148814
  7. Yang et al. Promoter knock-in mutations reveal a role of Mcl-1 in thymocyte-positive selection and tissue or cell lineage-specific regulation of Mcl-1 expression. J Immunol. 2009 ;182(5):2959-68. PMID: 19234191
  8. Han et al. Degradation of Mcl-1 by granzyme B: implications for Bim-mediated mitochondrial apoptotic events. J Biol Chem. 2004;279(21):22020-9. PMID: 15014070
  9. Han et al. Disruption of Mcl-1.Bim complex in granzyme B-mediated mitochondrial apoptosis. J Biol Chem. 2005;280(16):16383-92.PMID: 15713684
  10. Han et al. Interrelated roles for Mcl-1 and BIM in regulation of TRAIL mediated mitochondrial apoptosis. J Biol Chem.2006;281(15):10153-63.PMID: 16478725
  11. Han et al. Functional linkage between NOXA and Bim in mitochondrial apoptotic events. J Biol Chem. 2007;282(22):16223-31.PMID: 17374615
  12. Han et al. Deregulation of mitochondrial membrane potential by mitochondrial insertion of granzyme B and direct Hax-1 cleavage. J Biol Chem.2010;285(29:22461-72. PMID: 20388708
  13. Fung et al. Induction of autophagy during extracellular matrix detachment promotes cell survival. Mol Biol Cell. 2008;19(3):797-806. PMID: 18094039
  14. Chen et al. Targeting SQSTM1/p62 induces cargo loading failure and converts autophagy to apoptosis via NBK/Bik. Mol Cell Biol. 2014;34(18):3435-49.PMID: 25002530
  15. Tanno et al. Bim-dependent apoptosis follows IGFBP-5 down-regulation in neuroblastoma cells. Biochem Biophys Res Commun. 2006;351(2):547-52. PMID: 17067554

Related Products

Product NameProduct CodeSupplier 
Bim Peptide PSI-2065PProSci Summary Details